Answers are grounded in this paper and cite their sources.
Lixisenatide was more effective than placebo in patients with type 2 diabetes mellitus, and the mild-to-moderate adverse events were found to be tolerated during the follow-up.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: